Antiangiogenic effect of dual/selective α5 β1/αvβ3 integrin antagonists designed on partially modified retro-inverso cyclotetrapeptide mimetics

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 106-118

  Gentilucci, Luca ^a   Cardillo, Giuliana ^a   Spampinato, Santi ^a   Tolomelli, Alessandra ^a   Squassabia, Federico ^b   De Marco, Rossella ^a   Bedini, Andrea ^a   Baiula, Monica ^a   Belvisi, Laura ^c   Civera, Monica ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Stepbio srl Bologna   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOPEPTIDE; FIBRONECTIN; TETRAPEPTIDE; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DRUG CONFORMATION; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHAVBETA3; MODELS, CHEMICAL; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849140343     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9013532     Document Type: Article

References (80)

1. Brower, V. Tumor angiogenesis, new drugs on the block. Nat. Biotechnol. 1999, 17, 963-968.
2. Arndt, T.; Arndt, U.; Reuning, U.; Kessler, H. Integrins in angiogenesis: Implications for tumor therapy. In Cancer Therapy: Molecular Targets in Tumor-Host Interactions; Weber, G. F., Ed.; Horizon Bioscience: Norfolk, U.K., 2005.
3. Curley, G. P.; Blum, H.; Humphries, M. J. Integrin antagonists. Cell. Mol. Life Sci. 1999, 56, 427-441.
4. Brooks, P. C.; Clark, R. A.; Cheresh, D. A. Requirement of vascular integrin αvβ3 for angiogenesis. Science 1994, 264, 569-571.
5. Hynes, R. O. Areevaluation of integrins as regulators of angiogenesis. Nat. Med. 2002, 8, 918-921.
6. Reynolds, L. E.; Wyder, L.; Lively, J. C.; Taverna, D.; Robinson, S. D.; Huang, X.; Sheppard, D.; Hynes, R. O.; Hodivala-Dikle, K. M. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat. Med. 2002, 8, 27-34.
7. Cardarelli, P. M.; Lobl, T. J. Peptide inhibitors of β1 integrins. In Leukocyte Recruitment in Inflammatory Diseases; Peltz, G., Ed.; Springer: Heidelberg, Germany, 1996; pp 275-294.
8. Ruoslahti, E. Integrin signaling and matrix assembly. Tumor Biol. 1996, 17, 117-124.
9. Okada, N.; Watarai, M.; Ozeri, V.; Hanski, E.; Caparon, M.; Sasakawa, C. A matrix form of fibronectin mediates enhanced binding of Streptococcus pyogenes to host tissue. J. Biol. Chem. 1997, 272, 26978-26984.
10. Kim, S.; Harris, M.; Varner, J. A. Regulation of integrin αvβ3-mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J. Biol. Chem. 2000, 275, 33920-33928.
11. Ikari, Y.; Yee, K. O.; Schwartz, S. M. Role of α5β1 and αvβ3 integrins on smooth muscle cell spreading and migration in fibrin gels. Thromb. Haemostasis 2000, 84, 701-705.
12. Bewick, M. A.; Lafrenie, R. M. Adhesion dependent signalling in the tumour microenvironment: The future of drug targeting. Curr. Pharm. Des. 2006, 12, 2833-2848.
13. Mitjans, F.; Meyer, T.; Fittschen, C.; Goodman, S.; Jonczyk, A.; Marshall, J. F.; Reyes, G.; Piulats, J. Use of gastrin-releasing peptide promoter for specific expression of thymidine kinase gene in small-cell lung carcinoma cell. Int. J. Cancer 2000, 87, 716-723.
14. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding integrins. J. Biol. Chem. 2000, 275, 21785-21788.
15. Ruoslahti, E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 1996, 12, 697-715.
16. Thijssen, V. L. J. L.; van Beijnum, J. R.; Mayo, K. H.; Griffioen, A. W. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango. Curr. Pharm. Des. 2007, 13, 3576-3583.
17. Schmidmaier, R.; Baumann, P. Anti-adhesion evolves to a promising therapeutic concept in oncology. Curr. Med. Chem. 2008, 15, 978-990.
18. Ruoslahti, E.; Pierschbacher, M. D. Arg-Gly-Asp: A versatile cell recognition signal. Cell 1986, 44, 517-518.
19. DeSouza, S. E.; Ginsberg, M. H.; Plow, E. F. Arginyl-glycylaspartic acid (RGD): A cell-adhesion motif. Trends Biochem. Sci. 1991, 16, 246-250.
20. 3 integrin antagonists: Chemical and structural requirements for activity and selectivity. Mini-Rev. Med. Chem. 2002, 2, 531-42.
21. 3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide. J. Am. Chem. Soc. 1997, 119, 1328-1335.
22. Cacciari, B.; Spallato, G. Non peptidic αvβ3 antagonists: Recent developments. Curr. Med. Chem. 2005, 12, 51-70.
23. Pfaff, M.; Tangemann, K.; Müller, B.; Gurrath, M.; Müller, G.; Kessler, H.; Timpl, R.; Engel, J. Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3, αVβ3, and α5β1 integrins. J. Biol. Chem. 1994, 269, 20233-20238.
24. Gurrath, M.; Müller, G.; Kessler, H.; Aumailley, M.; Timpl, R. Conformation/activity studies of rationally designed anti-adhesive RGD peptides. Eur. J. Biochem. 1992, 210, 911-921.
25. 5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis 2003, 6, 105-119.
26. 3 integrin antagonists. J. Med. Chem. 1999, 42, 3033-3040.
27. Cai, W.; Chen, X. Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anticancer Agents Med. Chem. 2006, 6, 407-428.
28. Heckmann, D.; Kessler, H. Design and chemical synthesis of integrin ligands. Methods Enzymol. 2007, 426, 463-503.
29. Xiong, J.-P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Amin Arnaout, M. Crystal structure of the extracellular segment of integrin αvβ3 in complex with an Arg-Gly-Asp ligand. Science 2002, 296, 151-155.
30. Marinelli, L.; Lavecchia, A.; Gottschalk, K.-E.; Novellino, E.; Kessler, H. Docking studies on αvβ3 integrin ligands: Pharmacophore refinement and implications for drug design. J. Med. Chem. 2003, 46, 4393-4404.
31. 15N-edited 2D transferred nuclear Overhauser effects. J. Am. Chem. Soc. 2002, 124, 2862-2863.
32. Zimmermann, D.; Guthc-hrlein, E. W.; Malešević, M.; Sewald, K.; Wobbe, L.; Heggemann, C.; Sewald, N. Integrin α5β1 ligands: Biological evaluation and conformational analysis. ChemBioChem 2005, 6, 272-276.
33. 1 integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds. Bioorg. Med. Chem. 2007, 15, 7380-7390.
34. Takagi, J.; Strokovich, K.; Springer, T. A.; Walz, T. Structure of integrin α5β1 in complex with fibronectin. EMBO J. 2003, 22, 4607-4615.
35. Smallheer, J. M.; Weigelt, C. A.; Woerner, F. J.; Wells, J. S.; Daneker, W. F.; Mousa, S. A.; Wexler, R. R.; Jadhav, P. K. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg. Med. Chem. Lett. 2004, 14, 383-387.
36. 5 integrin receptor antagonist. Cancer Res. 2001, 61, 2232-2238.
37. Marinelli, L.; Meyer, A.; Heckmann, D.; Lavecchia, A.; Novellino, E.; Kessler, H. Ligand binding analysis for human α5β1 integrin: Strategies for designing new a5b1 integrin antagonists. J. Med. Chem. 2005, 48, 4204-4207.
38. Heckmann, D.; Meyer, A.; Marinelli, L.; Zahn, G.; Stragies, R.; Kessler, H. Probing integrin selectivity: Rational design of highly active and selective ligands for the α5β1 and αvβ3 integrin receptor. Angew. Chem., Int. Ed. 2007, 46, 3571-3574.
39. Gentilucci, L.; Cardillo, G.; Tolomelli, A.; Spampinato, S.; Sparta, A.; Squassabia, F. Cyclotetrapeptide mimics based on a 13-membered, partially modified retro-inverso structure. Eur. J. Org. Chem. 2008, 729-735.
40. Gentilucci, L.; Cardillo, G.; Tolomelli, A.; Squassabia, F.; De Marco, R.; Chiriano, G. Cyclopeptide analogs for generating new molecular and 3D diversity. Comb. Chem. High Throughput Screening 2009, 12, 929-939.
41. Schumann, F.; Muller, A.; Koksch, M.; Muller, G.; Sewald, N. Are β-amino acids γ-turn mimetics? Exploring a new design principle for bioactive cyclopeptides. J. Am. Chem. Soc. 2000, 122, 12009-12010.
42. Chorev, M.; Goodman, M. A dozen years of retro-inverso peptidomimetics. Acc. Chem. Res. 1993, 26, 266-273.
43. Chorev, M. The partial retro-inverso modification: A road traveled together. Biopolymers 2005, 80, 67-84.
44. Han, Y.; Giragossian, C.; Mierke, D. F.; Chorev, M. Ni-to -Ni+3-ethylene-bridged partially modified retro-inverso tetrapeptide β-turn mimetic: Design, synthesis, and structural characterization. J. Org. Chem. 2002, 67, 5085-5097.
45. Lee, Y. S.; Agnes, R. S.; Davis, P.; Ma, S.-w.; Badghisi, H.; Lai, J.; Porreca, F.; Hruby, V, J. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J. Med. Chem. 2007, 50, 165-168.
46. Fletcher, M. D.; Campbell, M. M. Partially modified retro-inverso peptides: Development, synthesis, and conformational behavior. Chem. Rev. 1998, 98, 763-795.
47. Glenn, M. P.; Kelso, M. J.; Tyndall, J. D. A.; Fairlie, D. P. Conformationally homogeneous cyclic tetrapeptides: Useful new three-dimensional scaffolds. J. Am. Chem. Soc. 2003, 125, 640-641.
48. Norgren, A. S.; Buttner, F.; Prabpai, S.; Kongsaeree, P.; Arvidsson, P. I. β2-Amino acids in the design of conformationally homogeneous cyclo-peptide scaffolds. J. Org. Chem. 2006, 71, 6814-6821.
49. Maulucci, N.; Chini, M. G.; Di Micco, S.; Izzo, I.; Cafaro, E.; Russo, A.; Gallinari, P.; Paolini, C.; Nardi, M. C.; Casapullo, A.; Riccio, R.; Bifulco, G.; De Riccardis, F. Molecular insights into Azumamide E histone deacetylases inhibitory activity. J. Am. Chem. Soc. 2007, 129, 3007-3012.
50. Gentilucci, L.; Cardillo, G.; Tolomelli, A.; De Marco, R.; Garelli, A.; Spampinato, S.; Spartà, A.; Juaristi, E. Synthesis and conformational analysis of cyclotetrapeptide mimetic β-turn templates and validation as 3D scaffolds. ChemMedChem 2009, 4, 517-523.
51. Nakabayashi, S.; Warren, C. D.; Jeanloz, R. W. The preparation of a partially protected heptasaccharide-asparagine intermediate for glycopeptide synthesis. Carbohydr. Res. 1988, 174, 279-289.
52. Morie, T.; Kato, S.; Harada, H.; Fujiwara, I.; Watanabe, K.; Matsumoto, J.-I. Ring expansion of nitrogen-containing chloromethylheteroalicycles via aziridinium intermediates. J. Chem. Soc., Perkin Trans. 1 1994, 2565-2569.
53. Conner, S. R.; Scott, G.; Aplin, A. E. Adhesion-dependent activation of the ERK1/2 cascade is by-passed in melanoma cells. J. Biol. Chem. 2003, 278, 34548-34554.
54. Park, K.; Kim, Y.-S.; Lee, G. Y.; Parl, R.-W.; Kim, I.-S.; Kim, S. Y.; Byun, Y. Tumor endothelial cell targeted cyclic RGDmodified heparin derivative: Inhibition of angiogenesis and tumor growth. Pharm. Res. 2008, 25, 2786-2798.
55. Lundell, B. I.; McCarthy, J. B.; Kovach, N. L.; Verfaillie, C. M. Activation-dependent α5β1 integrin-mediated adhesion to fibronectin decreases proliferation of chronic myelogenous leukemia progenitors and K562 cells. Blood 1996, 87, 2450-2458.
56. Belvisi, L.; Riccioni, T.; Marcellini, M.; Vesci, L.; Chiarucci, I.; Efrati, D.; Potenza, D.; Scolastico, C.; Manzoni, L.; Lombardo, K.; Stasi, M. M.; Orlandi, A.; Ciucci, A.; Nico, B.; Ribatti, D.; Giannini, G.; Presta, M.; Carminati, P.; Pisano, C. Biological and molecular properties of a new αvβ3/αvβ5 integrin antagonist. Mol. Cancer Ther. 2005, 4, 1670-1680.
57. Del Gatto, A.; Zaccaro, L.; Grieco, P.; Novellino, E.; Zannetti, A.; Del Vecchio, S.; Iommelli, F.; Salvatore, M.; Pedone, C.; Saviano, M. Novel and selective αvβ3 receptor peptide antagonist: Design, synthesis, and biological behavior. J. Med. Chem. 2006, 49, 3416-3420.
58. Giannis, A.; Rubsam, F. Integrin antagonists and other low molecular weight compounds as inhibitors of angiogenesis: New drugs in cancer therapy. Angew. Chem., Int. Ed. 1997, 36, 588-590.
59. Gentilucci, L.; Cardillo, G.; Squassabia, F.; Tolomelli, A.; Spampinato, S.; Sparta, A.; Baiula, M. Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg. Med. Chem. Lett. 2007, 17, 2329-2333.
60. Cheresh, D. A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. U.S. A. 1987, 84, 6471-6475.
61. Kawaguchi,M.; Hosotani, R.; Ohishi, S.; Fujii, N.; Singh Tulachan, S.; Koizumi,M.;Toyoda, E.;Masui,T.; Nakajima, S.; Tsuji, S.; Ida, J.;Fujimoto, K.;Wada,M.;Doi,R.; Imamura,M.Amovel synthetic Arg-Gly-Asp-containing peptide cyclo(-RGDf[dbond]V-) is the potent inhibitor of angiogenesis. Biochem. Biophys. Res. Commun. 2001, 288, 711-717.
62. Carmelit, P.; Jain, R. K. Angiogenesis in cancer and other diseases. Circ. Res. 2000, 87, 176-178.
63. Liotta, L.; Steeg, P.; Stetler-Stevenson, W. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991, 64, 327-336.
64. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
65. Kessler, H. Conformation and biological activity of cyclic peptide. Angew. Chem., Int. Ed. 1982, 21, 512-523.
66. Stradley, S. J.; Rizo, J.; Bruch, M. D.; Stroup, A. N.; Gierasch, L. M. Cyclic pentapeptides as models for reverse turns: Determination of the equilibrium distribution between type I and type II conformations of Pro-Asn and Pro-Ala β-turns. Biopolymers 1990, 29, 263-287.
67. 2O mixture as a biomimetic medium, see: Temussi, P. A.; Picone, D.; Saviano, G.; Amodeo, P.; Motta, A.; Tancredi, T.; Salvadori, S.; Tomatis, R. Conformational analysis of an opioid peptide in solvent media that mimic cytoplasm viscosity. Biopolymers 1992, 32, 367-372 and references cited herein .
68. Toniolo, C. Intramolecularly hydrogen-bonded peptide conformations. CRC Crit. Rev. Biochem. 1980, 9, 1-44.
69. HyperChem, release 8.0.3; Hypercube Inc.: Gainesville, FL, 2007.
70. Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
71. In a preliminary investigation of the conformational features of the PMRI RGD mimetics by ROESY and MD, we analyzed the insolution structural features of c[βPheψ(NHCO)Asp(Ot-Bu)ψ-(NHCO)Gly-Arg(Mtr)] (14) and c[(R)-βPheψ(NHCO)Asp(Ot-Bu)ψ(NHCO)Gly-Arg(Mtr)], the protected synthetic precursors of 2 and 3, respectively. While the conformation of fully protected 2 (14) was practically coincident to the type I β-turn/ type I β-turn structure of 2 (Figures 5 and 6), the predominant conformation of fully protected 3 was compatible with the inverse γ/inverse γ structure reported in Figure 8. Apparently, increasing the size of the side chains of the PMRI CTPs tends to stabilize the inverse γ/ inverse γ structure over the type II β-turn structure (Figure 8).
72. Glide, version 4.5; Schrödinger, LLC: New York, 2007.
73. 3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
74. Kim, S.; Bell, K.; Mousa, S.; Varner, J. A. Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 2000, 156, 1345-1362.
75. Hunakova, L.; Sedlak, J.; Klobusicka, M.; Sulikova, M.; Chorvath, B. Phorbol ester (TPA)-induced differential modulation of cell surface antigens in human pluripotential leukemia (K-562) cell line: Effects of protein kinase inhibitors with broad and PKC selective inhibitory activity. Neoplasma 1995, 42, 249-253.
76. Caltabiano, S.; Hum, W. T.; Attwell, G. J.; Gralnick, D. N.; Budman, L. J.; Cannistraci, A. M.; Bex, F. J. The integrin specificity of human recombinant osteopontin. Biochem. Pharmacol. 1999, 58, 1567-1578.
77. Shibata, H.; Yagi, T. Rate assay of N-acetyl-β-D- hexosaminidase with 4-nitrophenyl N-acetyl-β-D-glucosaminide as an artificial substrate. Clin. Chim. Acta 1996, 251, 53-64.
78. Maeshima, Y.; Manfredi, M.; Reimer, C.; Holthaus, K. A.; Hopfer, H.; Chandamuri, B. R.; Kharbanda, S.; Kalluri, R. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J. Biol. Chem. 2001, 276, 15240-15248.
79. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81, 3684-3690.
80. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.